HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.

Abstract
New therapeutic agents are needed for the treatment of androgen-independent prostate cancer (PrCa). We have investigated the effect of methylseleninic acid (MSA) on tumor stage-specific prostate cells derived from the C3 (1)/Tag model for PrCa: Pr111, a slow-growing and nontumorigenic cell line isolated from a prostate intraepithelial neoplasia lesion; Pr14, a tumorigenic line derived from a primary tumor; and Pr14C1, a sub-clone of Pr14 explanted from a lung metastasis. We demonstrate that MSA strongly inhibits cell growth and induces apoptosis in C3 (1)/Tag tumor cells, in a dose-dependent manner. A decrease in phosphorylated ERK1/2 and AKT was also found in tumor cells, but not in Pr111. Microarray analysis using affymetrix showed that the number of genes with an altered expression in tumor cells is significantly higher (p < 0.01) than in nontumoral cells. Pathways analyses revealed a decrease in the expression of genes involved in metabolism (Fabp5, Cyba), signal transduction (ERK, AKT), angiogenesis (neuropilin-1, Flt-4) and transcription (cAMP response element-binding protein) in tumor cells. The expression of neuropilin-1, a protein involved in VEGF signaling and tumor angiogenesis, was 97-fold repressed in Pr14 cells treated with MSA. Combination treatments using low doses of etoposide or taxotere (docetaxel), plus low doses of MSA revealed a strong enhancement of cell growth inhibition and apoptosis in tumor cells. Our in vivo studies using Pr14 cells xenografted into nude mice demonstrated that MSA significantly enhances the chemotherapeutical effect of etoposide, resulting in 78.3% tumor growth inhibition. These results suggest that MSA could be used against PrCa to enhance the effect of etoposide.
AuthorsOscar Gonzalez-Moreno, Victor Segura, Diego Serrano, Paul Nguewa, Javier de las Rivas, Alfonso Calvo
JournalInternational journal of cancer (Int J Cancer) Vol. 121 Issue 6 Pg. 1197-204 (Sep 15 2007) ISSN: 0020-7136 [Print] United States
PMID17520673 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright(c) 2007 Wiley-Liss, Inc.
Chemical References
  • Antineoplastic Agents
  • Organoselenium Compounds
  • Taxoids
  • Docetaxel
  • Etoposide
  • methylselenic acid
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Apoptosis (drug effects)
  • Blotting, Western
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Docetaxel
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Etoposide (pharmacology)
  • Gene Expression (drug effects)
  • Gene Expression Profiling
  • Humans
  • Male
  • Metabolic Networks and Pathways (drug effects)
  • Mice
  • Mice, Nude
  • Oligonucleotide Array Sequence Analysis
  • Organoselenium Compounds (pharmacology)
  • Prostatic Neoplasms (drug therapy)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction (drug effects)
  • Taxoids (pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: